CAJ | 학술논문

目的：分析我院鲍曼不动杆菌的分布特征及耐药现状，为临床防治方案的制定提供依据。方法运用VITEK 2 compact全自动微生物鉴定仪对2013年6月至2013年12月我院临床分离的不动杆菌属菌株进行菌种鉴定，选用VITEK 2药敏试验卡AST-GN13进行鲍曼不动杆菌对17种抗菌药物的药敏试验，分析患者临床资料及鲍曼不动杆菌药敏试验结果。结果我院鲍曼不动杆菌在627株不动杆菌属临床分离株中的分离率为86．3％（541/627），该菌主要分布于50岁以上年龄组，占84．1％（455/541），痰液标本分离率最高为85．2％（461/541），主要分布于ICU（35．7％，193/541）和呼吸内科病区（25．5％，138/541）；临床常用的17种抗菌药物中，仅对亚胺培南耐药率较低为28．8％，多重耐药鲍曼不动杆菌占64．5％（349/541）。结论鲍曼不动杆菌为不动杆菌属主要临床分离菌，主要引起老年患者、ICU患者呼吸道感染。该菌呈现高耐药率，多重耐药现象严峻。
목적：분석아원포만불동간균적분포특정급내약현상，위림상방치방안적제정제공의거。방법운용VITEK 2 compact전자동미생물감정의대2013년6월지2013년12월아원림상분리적불동간균속균주진행균충감정，선용VITEK 2약민시험잡AST-GN13진행포만불동간균대17충항균약물적약민시험，분석환자림상자료급포만불동간균약민시험결과。결과아원포만불동간균재627주불동간균속림상분리주중적분리솔위86．3％（541/627），해균주요분포우50세이상년령조，점84．1％（455/541），담액표본분리솔최고위85．2％（461/541），주요분포우ICU（35．7％，193/541）화호흡내과병구（25．5％，138/541）；림상상용적17충항균약물중，부대아알배남내약솔교저위28．8％，다중내약포만불동간균점64．5％（349/541）。결론포만불동간균위불동간균속주요림상분리균，주요인기노년환자、ICU환자호흡도감염。해균정현고내약솔，다중내약현상엄준。
Objective To investigate clinical distribution and drug resistance of Acinetobacter bau-mannii in our hospital so as to provide evidence for clinical prevention and treatment programs. Methods Species identification of clinical isolates from Jun. 2013 to Dec. 2013 was performed using VITEK 2 compact instrument. The susceptibility of Acinetobacter baumannii isolates to 17 antibiotics was determined using VITEK 2 AST-GN13 card. The clinical datas and the results were analyzed. Results Of 627 Acinetobacter spp., there were 541 strains of Acinetobacter baumannii isolated with the detection rate of 86.3%(541/627). The patients older than 50 years were in the majority for clinical Acinetobacter baumannii infection in our hos-pital with the distribution rate of 84.1%(455/541). The highest relevance ratio of specimen was sputum with the rate of 85.2%(461/541). ICU separation rate (35.7%, 193/541) was the highest and followed by depart-ment of respiratory medcine (25.5%, 138/541). To 17 kinds of common clinical antibacterials, the resistance rate of imipenem was the lowest (28.8%), other antimicrobial resistance rates were higher than one third. The rate for multiple drug resistance was 64.5%(349/541). Conclusion The main species is Acinetobacter bau-mannii among Acinetobacter spp. clinical isolates. Acinetobacter baumannii clinical isolates mainly cause el-derly and intensive care patients suffer from respiratory tract infection, and show high level of drug resistance, significantly high detection rate of multiple drug resistance phenotype.